Synthetic Biologics, Inc. (SYN) |
1.02 0.01 (0.99%)
|
10-12 15:59 |
Open: |
1.02 |
Pre. Close: |
1.01 |
High:
|
1.02 |
Low:
|
0.9724 |
Volume:
|
57,789 |
Market Cap:
|
16(M) |
|
|
Technical analysis |
as of: 2023-01-27 4:48:22 PM |
Overall:
|
|
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
Target: |
Six months: 1.19 One year: 1.39 |
Support: |
Support1: 0.99 Support2: 0.97 |
Resistance: |
Resistance1: 1.01 Resistance2: 1.19 |
Pivot: |
0 |
Moving Average: |
MA(5): 0 MA(20): 0
MA(100): 0 MA(250): 0 |
MACD: |
MACD(12,26): 0 Signal(9): 0 |
Stochastic oscillator: |
%K(14,3): 0 %D(3): 0 |
RSI: |
RSI(14): 0 |
52-week: |
High: 1.01 Low: 0.97 |
Average Vol(K): |
3-Month: 0 (K) 10-Days: 0 (K) |
|
Price, moving averages and Bollinger Bands |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ SYN ] has closed Bollinger Bands are 0% narrower than normal. |
|
Stock Price Prediction |
Update at 5:00pm EST |
If tomorrow:
|
Open lower
|
Open higher
|
High:
|
- |
- |
Low:
|
- |
- |
Close:
|
- |
- |
|
Company Description |
Synthetic Biologics, Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. It also develops VCN-01 for the treatment of patients with pancreatic cancer, head and neck squamous cell carcinoma, colorectal cancer, and retinoblastoma. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics; SYN-005 for the prevention and treatment of pertussis; and VCN-11 to treat cancer. It has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center; and a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Synthetic Biologics, Inc. is headquartered in Rockville, Maryland. |
Headline News |
Sun, 29 Jan 2023 The Week In Photos 1/22/23 – 1/29/23 — The Heights - The Heights
Sat, 28 Jan 2023 Cutie Pie 2 You - Episode 2 "Love or Dream" Recap & Review - TheReviewGeek
Sat, 28 Jan 2023 CCH vs SYN Dream11 Team Prediction, Chattogram Challengers vs ... - Cricket Country News
Thu, 26 Jan 2023 Mind, Blown: There Are Only *Two* Plant-Based Foods That Contain Saturated Fat, According to RDs - Well+Good
Wed, 25 Jan 2023 Royal DSM Achieves Approval for SYN-UP Under China's Latest ... - Cosmetics & Toiletries
Wed, 25 Jan 2023 Top Analyst Forecasts Imminent XRP Surge, Says Bitcoin and One Low-Cap Altcoin Set To Rally - The Daily Hodl
|
Financial Analysis |
Price to Book Value: |
Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Price to Earnings: |
Underperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Discounted cash flow: |
Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Return on Assets: |
Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Return on Equity: |
Neutral |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Debt to Equity: |
Neutral |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
Free Technical Analysis Charts
|
|
Stock Basics & Statistics |
Exchange: AMEX |
Sector: Healthcare |
Industry: Biotechnology |
Shares Out. |
0 (M) |
Shares Float |
0 (M) |
% Held by Insiders
|
0 (%) |
% Held by Institutions
|
0 (%) |
Shares Short
|
0 (K) |
Shares Short P.Month
|
0 (K) |
Stock Financials |
EPS
|
0 |
EPS Est Next Qtl
|
0 |
EPS Est This Year
|
0 |
EPS Est Next Year
|
0 |
Book Value (p.s.)
|
0 |
Profit Margin (%)
|
0 |
Operating Margin (%)
|
0 |
Return on Assets (ttm)
|
0 |
Return on Equity (ttm)
|
0 |
Qtrly Rev. Growth
|
0 |
Gross Profit (p.s.)
|
0 |
Sales Per Share
|
0 |
EBITDA (p.s.)
|
0 |
Qtrly Earnings Growth
|
0 |
Operating Cash Flow
|
0 (M) |
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
PE Ratio
|
0 |
PEG Ratio
|
0 |
Price to Book value
|
0 |
Price to Sales
|
0 |
Price to Cash Flow
|
0 |
Stock Dividends |
Dividend
|
0 |
Forward Dividend
|
0 |
Dividend Yield
|
0% |
Dividend Pay Date
|
Invalid DateTime. |
Ex-Dividend Date
|
Invalid DateTime. |
Your Ad Here
|
|